医学
英夫利昔单抗
炎症性肠病
炎症性肠病
溃疡性结肠炎
免疫学
肿瘤坏死因子α
皮肤病科
内科学
疾病
作者
Jagadeshwar G. Reddy,Edward V. Loftus
标识
DOI:10.1016/j.gtc.2006.09.008
摘要
In many ways, infliximab has drastically altered expectations for medical therapy in IBD, and it is expected that adalimumab and certolizumab pegol with ultimately have a similar role. Patients initiating such therapy should be made cognizant of the potential risks of serious infection including opportunistic ones, such as TB and histoplasmosis; demyelinating disorders; CHF; and lymphoma. Proper selection of candidates for anti-TNF-alpha therapy is critical in maintaining a proper benefit-to-risk ratio.
科研通智能强力驱动
Strongly Powered by AbleSci AI